Cingulate Inc.

NASDAQ: CINGW · Real-Time Price · USD
0.04
-0.00 (-4.76%)
At close: May 01, 2025, 11:40 AM
0.04
0.00%
After-hours: May 01, 2025, 04:00 PM EDT
-4.76%
Bid 0.03
Market Cap 149.77K
Revenue (ttm) n/a
Net Income (ttm) -3.24B
EPS (ttm) -1.732
PE Ratio (ttm) -0.02
Forward PE n/a
Analyst n/a
Ask 0.04
Volume 2,932
Avg. Volume (20D) 57,664.621
Open 0.03
Previous Close 0.04
Day's Range 0.03 - 0.04
52-Week Range 0.03 - 0.04
Beta -0.88

About CINGW

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was fo...

Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CINGW
Full Company Profile
No News article available yet